Explore All Access
Check if your research matches the topics covered in Investigational New Drugs?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Investigational New Drugs : Impact Factor & More
eISSN: 1573-0646pISSN: 0167-6997
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Investigational New Drugs Key Metrics
CiteScore 
6.2
Eigenfactor
0.005 - 0.01
H-Index
94
Impact Factor
< 5
SJR
Q1Oncology
SNIP
0.85
Time to Publish
View Chart Mo
Topics Covered on Investigational New Drugs
Drug discovery
Cancer
Lung cancer
Maximum tolerated dose
Whole blood
Bioinformatics analysis
Hepatocellular carcinoma
Toxicity
Signal transduction
Breast cancer
Immunotherapy
Oral administration
Epidermal growth factor receptor
Nivolumab
Chemoradiotherapy
Overall survival
Erlotinib
Microscale thermophoresis
Mesothelioma
Progression-free survival
Investigational New Drugs Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
One subscription packed with expert publication services and AI tools to get you published
Brought to you by 
Journal Selection Service
Benefit from our experts' recommendations of 3-5 best-suited journals, accompanied by a detailed Journal Selection report explaining the choices. Make informed decisions.
Journal Submission Service
Streamline your submission process with meticulous manuscript formatting to meet journal guidelines, crafting a tailored cover letter for the editor, and hassle-free account creation and submission
Bundle of AI tools for your research needs
Journal Finder, Paperpal, R Discovery, MindTheGraph and more
Time to Publish
% of papers by time taken from submission to publication
0 to 3 months62%
4 to 6 months33%
7 to 9 months2%
Above 9 months3%
Did you find this useful?
Planning to publish in Investigational New Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Investigational New Drugs
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
- 6 Mar 2024
- Investigational New Drugs
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages
- 1 Mar 2024
- Investigational New Drugs
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
- 22 Feb 2024
- Investigational New Drugs
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer
- 17 Feb 2024
- Investigational New Drugs
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
- 12 Feb 2024
- Investigational New Drugs
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
- 1 Feb 2024
- Investigational New Drugs
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
- 6 Mar 2024
- Investigational New Drugs
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages
- 1 Mar 2024
- Investigational New Drugs
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
- 22 Feb 2024
- Investigational New Drugs
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer
- 17 Feb 2024
- Investigational New Drugs
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
- 12 Feb 2024
- Investigational New Drugs
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
- 1 Feb 2024
- Investigational New Drugs
Compare Similar Journals with Investigational New Drugs
Select Journals to Compare with Investigational New Drugs
Total journals - 10
You can select up to 3 Journals at a time
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Annals of Oncology
Publisher: ELSEVIER
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Cancer Chemotherapy and Pharmacology
Publisher: SPRINGER
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
BMC Cancer
Publisher: BMC
Journal for ImmunoTherapy of Cancer
Publisher: BMJ PUBLISHING GROUP
0 Journals Selected to compare with
Investigational New Drugs
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Investigational New Drugs
How long has Investigational New Drugs been actively publishing? 
Investigational New Drugs has been in operation since 1983 till date.
What is the publishing frequency of Investigational New Drugs?
Investigational New Drugs published with a Bi-monthly frequency.
How many articles did Investigational New Drugs publish last year?
In 2023, Investigational New Drugs publsihed 27 articles.
What is the eISSN & pISSN for Investigational New Drugs?
For Investigational New Drugs, eISSN is 1573-0646 and pISSN is 0167-6997.
What is Citescore for Investigational New Drugs?
Citescore for Investigational New Drugs is 6.2.
What is the H Index for Investigational New Drugs ?
H Index for Investigational New Drugs is 94.
What is SNIP score for Investigational New Drugs?
SNIP score for Investigational New Drugs is 0.85.
What is the SJR for Investigational New Drugs?
SJR for Investigational New Drugs is Q1.
Who is the publisher of Investigational New Drugs?
SPRINGER is the publisher of Investigational New Drugs.
